Who
Timothy Keutzer
Chief Operating Officer
Company insider
Files Form 4 as: Chief Operating Officer, Spero Therapeutics.
In numbers
- Trades disclosed
- 28
- Buys
- 0
- Sells
- 10
- Bought
- $0
- Sold
- $392K
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 3 Feb 2020
- Last trade
- 6 Feb 2026
- Last filed
- 9 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 6 Feb 2026filed 9 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $44K18,652 at $2.36 | filing |
| 6 Feb 2026filed 9 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $44K18,652 at $2.36 | filing |
| 4 Feb 2026filed 5 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,7753,471 at $2.24 | filing |
| 4 Feb 2026filed 5 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $7,7753,471 at $2.24 | filing |
| 3 Feb 2026filed 5 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $52K24,224 at $2.14 | filing |
| 3 Feb 2026filed 5 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $52K24,224 at $2.14 | filing |
| 2 Feb 2026filed 5 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —68,000 at $0.00 | filing |
| 2 Feb 2026filed 5 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $42K18,891 at $2.20 | filing |
| 2 Feb 2026filed 5 Feb 2026 | SPRO Spero Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —137,000 at $0.00 | filing |
| 2 Feb 2026filed 5 Feb 2026 | SPRO Spero Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —137,000 at $0.00 | filing |
| 2 Feb 2026filed 5 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —68,000 at $0.00 | filing |
| 2 Feb 2026filed 5 Feb 2026 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $42K18,891 at $2.20 | filing |
| 28 Aug 2025filed 3 Sep 2025 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,3391,695 at $1.97 | filing |
| 5 Feb 2025filed 5 Feb 2025 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $3,1003,974 at $0.78 | filing |
| 5 Feb 2025filed 5 Feb 2025 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $22K27,643 at $0.78 | filing |
| 5 Feb 2025filed 5 Feb 2025 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $19K24,920 at $0.78 | filing |
| 3 Feb 2025filed 5 Feb 2025 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —266,139 at $0.00 | filing |
| 27 Aug 2024filed 29 Aug 2024 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $2,9882,213 at $1.35 | filing |
| 2 Feb 2024filed 5 Feb 2024 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Sold | $42K30,971 at $1.36 | filing |
| 1 Feb 2024filed 5 Feb 2024 | SPRO Spero TherapeuticsBiotechnology | SEC FORM 4 Code A | —239,731 at $0.00 | filing |
News
Spero Therapeutics to Participate in the Chardan 10th Annual Healthcare ConferenceSPRO · manilatimes.net · 15 Oct 2026
0 headlines in the last 90 days name Timothy Keutzer; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.